Irinotecan
ALK Gene Rearrangement Positive
Instituto Nacional de Cancerologia de MexicoSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the ALK Gene Rearrangement Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ALECTINIB Instituto Nacional de Cancerologia de Mexico | Phase 2 | B |
(+)-VINCRISTINE Instituto Nacional de Cancerologia de Mexico | Phase 2 | B |
Carboplatin Dr Joanne CHIU | Phase 2 | B |
Atezolizumab Centre Francois Baclesse | Phase 2 | B |
Pembrolizumab Dr Joanne CHIU | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →